LIGAND PHARMACEUTICALS INCORPORATED Deferred Tax Assets, Valuation Allowance
LIGAND PHARMACEUTICALS INCORPORATED (LGNYZ) had Deferred Tax Assets, Valuation Allowance of $48.33 million as of 2025-12-31, per its 10-K filed 2026-02-27.
Financial Statements › Notes › Income Taxes › Components of Deferred Tax Assets and Liabilities › Components of Deferred Tax Assets › Deferred Tax Assets, Net › Deferred Tax Assets, Net of Valuation Allowance
us-gaap:DeferredTaxAssetsValuationAllowance · last filed 2026-02-27
- 2025-12-31: Deferred Tax Assets, Valuation Allowance $48.33M.
- 2024-12-31: Deferred Tax Assets, Valuation Allowance $55.65M.
- 2023-12-31: Deferred Tax Assets, Valuation Allowance $57.70M.
- 2022-12-31: Deferred Tax Assets, Valuation Allowance $57.47M.
| Period end | Deferred Tax Assets, Valuation Allowance | Deferred Tax Assets, Valuation Allowance as first filed |
|---|---|---|
| 2025-12-31 | $48.33M 10-K · filed 2026-02-27 | |
| 2024-12-31 | $55.65M 10-K · filed 2026-02-27 | |
| 2023-12-31 | $57.70M 10-K · filed 2025-02-28 | |
| 2022-12-31 | $57.47M 10-K · filed 2024-02-29 | |
| 2021-12-31 | $35.93M 10-K · filed 2023-02-28 | $36.28M 10-K · filed 2022-02-28 |
| 2020-12-31 | $24.86M 10-K · filed 2022-02-28 | |
| 2019-12-31 | $141.34M 10-K · filed 2021-02-24 | |
| 2018-12-31 | $4.48M 10-K · filed 2020-02-27 | |
| 2017-12-31 | $6.99M 10-K · filed 2019-02-28 | |
| 2016-12-31 | $15.35M 10-K · filed 2018-03-01 | |
| 2015-12-31 | $9.07M 10-K · filed 2017-02-28 | |
| 2014-12-31 | $240.42M 10-K · filed 2016-11-14 | $249.47M 10-K · filed 2014-12-01 |
| 2013-12-31 | $249.47M 10-K · filed 2015-02-23 | |
| 2012-12-31 | $254.87M 10-K/A · filed 2014-12-12 | |
| 2011-12-31 | $213.10M 10-K · filed 2013-03-14 |